Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (231-240 of 418) with videos related to

Pageof 42
Sort By:
Cancer Discovery|February 6, 2026
Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in MelanomaMaria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Science Signaling|March 27, 2014
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signalingBerta Sanchez-Laorden, Amaya Viros, Maria Romina Girotti, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of <i>BRAF</i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
Cancers|August 14, 2025
Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT StudyJavier Pozas, Sowmya Cheruvu, Poorni Priya Jaganathan, et al.
JAMA Oncology|December 8, 2022
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without IpilimumabJennifer L McQuade, Hans Hammers, Helena Furberg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Journal for Immunotherapy of Cancer|April 5, 2024
Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitisCathrin L C Gudd, Eoin Mitchell, Stephen R Atkinson, et al.
Research Square|December 18, 2023
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinomaRichard Houlston, Richard Culliford, Sam Lawrence, et al.
The Oncologist|June 8, 2019
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid TumorsM Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
Pageof 42

Showing results (231-240 of 418) with videos related to

Sort By:
Pageof 42
Cancer Discovery|February 6, 2026
Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in MelanomaMaria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Science Signaling|March 27, 2014
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signalingBerta Sanchez-Laorden, Amaya Viros, Maria Romina Girotti, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of <i>BRAF</i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
Cancers|August 14, 2025
Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT StudyJavier Pozas, Sowmya Cheruvu, Poorni Priya Jaganathan, et al.
JAMA Oncology|December 8, 2022
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without IpilimumabJennifer L McQuade, Hans Hammers, Helena Furberg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Journal for Immunotherapy of Cancer|April 5, 2024
Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitisCathrin L C Gudd, Eoin Mitchell, Stephen R Atkinson, et al.
Research Square|December 18, 2023
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinomaRichard Houlston, Richard Culliford, Sam Lawrence, et al.
The Oncologist|June 8, 2019
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid TumorsM Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
Pageof 42